PLx Pharma Winddown (PLXPQ) 14 May 212021 Q1 Earnings call transcript

Good day and, thank you for standing by. Welcome to the PLx Pharma's Q1 2021 Earnings Call. [Operator Instructions] I would now like to hand the conference over to Lisa Wilson, Investor Relations for PLx.

Thank you, Amitris [ph]. Welcome to PLx Pharma’s Q1 2021 earnings results call. Investor PLx. Wilson, Lisa is Relations for This With and O’Connor, Chief today’s call Chief Giordano, President are Natasha Executive Officer PLx. me of on Financial Officer; and Rita

the webcast You access website of Investors section this at can plxpharma.com. of the call also PLx the through

on started, expectation, made forward-looking projection, events or regarding conference we forecast, any get remind and that express by the Reform defined Litigation future future as considered would anticipation statements I Before call performance the to that like everyone Securities statements today’s belief, maybe company’s a intent Private Act.

performance. the forward-looking on materially Forward-looking Actual release in to Such statements be our press days including on statements. PLx not those or except website, are are Pharma’s disclaims available future The forward-looking based and noted plxpharma.com. for and the those XX information issued today webcast statements, this as update statements law. involve uncertainties, as SEC. risks of management forward-looking with projected obligation results guarantees any of morning by archived intent our differ specifically PLx and in these available to from may filings will required our

releases who so webcast, please to Since reference Natasha the Giordano. and discussed, maybe SEC of replay turn most or may PLx’s And the and have press the archived filings. I CEO, PLx over then, will For to benefit on May the to call related this topics the those held was with XXXX. call listening recorded XX, made that, recent announcements company’s

for you and Lisa. today. Thank everyone you, Good us thank morning, joining

milligrams doses. received recently reminder, XXX a we approval milligram FDA of XX As and VAZALORE

with millions aspirin can benefit vascular only capsule liquid filled of The first disease. and that patients

to or has of debilitating in been family to excited to a us VAZALORE friends And we mind always from a or passion. them. the Having are the VAZALORE who effects We wonder attack what patient heart has suffered our Every top available had of close of have if the third one always market was quarter. stroke. bring

the reliable and predictable VAZALORE, realized. FDA vision can Now patients of be has our that approved aspirin to risk at therapy bringing a

to community to patients. We to VAZALORE forward word medical the thrilled launch to and out and the getting are look

at large commercial patients is estimated million already market This groups. clinical with a billion. trial. the two disease in an event, guidance care. a those standard under attack who candidates physician. may of the at therapy such We will thus VAZALORE -- risk with heart vascular This more as event have is opportunity of risk GI diabetes platelet used the those $XX market world. innovation novel a and been is decades. in drug widely the a limitations aspirin. the fast, in absorbed in Aspirin care, observed yet and aspirin inhibition, published Until current the VAZALORE as aspirin most there's addressing as erosions the significantly reduces risk and category been the VAZALORE radically And of demonstrates thus in and the result, the high and defined includes having be like predictable delivers their tract who an from enteric-coated or immediate-release enteric-coated ulcers believe no in It's reliable our VAZALORE aspirin that standard for now. suffered stomach in with transform and retail way are stroke, XX aspirin of well-established of than of Patients

to and up is extensively strategy Bhatt scientific patents Deepak O’Connor. is our experts seriousness chaired quite mechanism this scientific And doctors have product. been patient the into by in clinicians what's in reason among group, vascular of cardiology, XX and guiding over-the-counter published who Rita the advisory and The our extended important board treat appreciates I'll to of Rita? instrumental over now the for and turn call has unique the understanding made unique finally, need VAZALORE's advisory the Dominick CFO, neurology Angiolillo. board renowned world delivery of gastroenterology, unmet disease. of we Importantly, our XXXX, and an esteemed

X.X busy our This for exciting And prepare we a now us you, commissions, offering bring proceeds we Thank our $X. time March, to In stock were expenses. an deducting million the a patients. $XX.X at offering discounts, to to to public capital on execute vision price and we million underwritten VAZALORE of have Gross as and closed common other launch of of Natasha. of is millions before VAZALORE shares successfully. underwriting on

of first cash in quarter. our due cash sheet. February with XXXX, million no have XX, paid We of on equivalents now March we cash of a off $X.X had term loan balance burn our and million, As debt the of $XX.X the and for balance

Our $XX support years. next the X million for existing to sufficient be for cash commercial activities of should least at our VAZALORE

On launch load, the of already packaging the end very begin VAZALORE this to manufacturing front, month. we for significant capsules our are we're and progress. of making manufactured portion excellent excited We've at a

plant continue to country supply and across summer. inventory We build the retailers sufficient to ready packaged product this have

burn be quarter million cash $X to 'XX. expect around of We second for the

the will significantly as our contract the the inventory become in burn third and increase up sales payments of major quarter, ramps the spend portion manufacturers. due cash and However, marketing of to

With call closer sharing retailers move sales product placement orders more to and Natasha. will look over I from back launch, spend. marketing and to turn to we details that, forward we As around the

Rita. you, Thank

launch need be real the treatment positioned gets to lipid-aspirin VAZALORE, who of stomach innovation this let how you can liquid with so VAZALORE addresses VAZALORE share uniquely many who around For that disease in benefit. product, of me a those to to the management capsules this of some the duodenum. are the differentiators, is line bypasses of filled highlights in team excited unique its vascular top rapidly a new the so complex absorbed unmet may and it and why and

inhibition of compared enteric-coated with the and As absorption standard current platelet a VAZALORE faster, provides aspirin more result, aspirin, reliable care.

aspirin, for cardiologists. comparison regular VAZALORE published pharmacodynamic formulations, top robust American the and was journal Our reviewed College the pharmacokinetic enteric-coated of Cardiology, study, clinical in of peer Journal aspirin the a of three and

and causes ulcers also as VAZALORE erosions fewer with regular Importantly, aspirin. compared gastric

the assessment educating and endoscopic Journal was conferences. medical GI of American continuing medical weekend Gastroenterology. the of our American exhibiting College data to We approved, our and of consumer, The at most believe and community, medical firmly data. delivery compelling Session. informing management a and that commitment ACC the XXth strategies, from unique Cardiology's the the this Our cardiology experience and education the filled damage patients the stakeholders; We're regular our and trade Annual of we're aspirin participate. raising as only excited depth about in published capsule, This winning its combination among to to successful of and liquid represents in the our our is conferences Scientific aspirin [indiscernible] supporting key focus the we're FDA comparison on Central team's three published clinical retail for VAZALORE and mechanism prestigious community, upper awareness, launch. the and our support a marketing first clinical world

excited we launch do in With what hand, the FDA VAZALORE the PLx to products. do best, team approvals is

household few. to launched Mucinex, household Zantac has is name. forward to name and and in that built relevant experience VAZALORE launches buying look challenges brands of segments and highly management This the in successfully. a Zicam, just of launching consumers make We HCPs clinical depth Lipitor, their names face practice including understand how Our a decisions. turning many across we into the involved VAZALORE to prescription team been team successfully and products successful has the Collectively, and our leadership OTC mega

distribution also recognizable will channels. We with trade we with Operator, and have intricacies questions. how for go extensive I know know the We instructions. the markets, strong, ahead we the know experience With constituents the that, the most the understand key penetrating please brands. big retail open build U.S and customers to of call importantly,

Elliot the Wilbur first question Raymond Instructions] with from [Operator comes James. Your of line

Rita. Good morning, Natasha, Thanks.

forward Looking … to

Good morning.

to VAZALORE visible maybe publication may and visibility forward we or first the share should us market on could store you seeing shelves I question may looking VAZALORE at just to of since lead that side last launch? with for guess, of of national of efforts activity as to into the a full sort any corollary relatively be in external that strategy retail priming level soon. the call, your more And the would preparation headed that, looking be that the launch. on enhance signs advance the … anything

he's our company tell retail And their conferences, all will Good strategy the the about health more in Yes, retail with cardiologist will months. now, prepared the we Elliot. also get we're in medical market. it but the next of as at along in equally Sure. the all partnering, the preparing morning, through to the be years. role our been in when the doing in you we as trade in understanding have the product, veteran as get talk we we terms early way of position on getting have And of known. coming customers gone to to prepared, when been to Obviously, they providing launch. a that of stores He's are with Sales, we'll XX planning He's terms And many, the meetings, has but and community for care our lot how level. right the be we VAZALORE can't a moments together about Steve close upon meetings Valentino an closer talk commitments industry many and Trade and from that variety that of us. well more couple preparing, we having companies VP to

Okay.

of the are as to Rita and -- of our in though, this national you well. in as terms country for level I manufacturing we we're Elliot, presentation, In part a her that can't launch say preparing heard

not recently guess Looks at question usual Then looked XX aspirin. that of trial of platelet to other milligrams just inhibition but just like earlier had studies that clinical ones AEs, trial, are initiated be some one for with points in the of the being a some enteric-coated might Okay. I any curious looking I the that company's VAZALORE sort comparing seen the additional you parameters you. the parameters gain may that or data you XXX? into insight we from with that have did and

milligram already but XX your to only. Yes, VAZALORE doses. two trial want both immediate We're XXX the FDA with like is terms Yes, elements to purposes we we FDA I XX commercial that milligrams, of a midst also clearly, our are behaves clinical question. for as release in complete show think aspirin bioequivalent the milligram determined. there's the to approvals of on And conducting has in

that metrics. will I and those plan. near We parameters future. your answer results that the pharmacodynamic I'm publication And forward in that be into before pharmacokinetic and And primary didn't looking looking our data is as other and our ties to at having question on

We very strategy. are committed plan to a publication much and

involved. heavily are Bhatt Deepak Dr. by led Board Advisory Scientific Our

a our with of have plans drafting different as continue committee publication a And We we're number manuscripts. those advisors.

You year those remember may different of last abstracts are at manuscripts. being that a into number now conferences, and we converted the posters presented

because I get you to be as community enteric-coated the think So it's it more our for tablet. will so to seeing on scientific aspirin relates information continue the to product important medical

Okay, thank you. Those were my questions.

Elliot Wilbur. you, Thank

Your JMP the next question from Jason of Butler Securities. with line comes

Jason. just And retailers, I’m of maybe the versus on the a I'm the summer launch for either it that expecting the you've gotten taking start curious planning in XQ a our robust quarters little the closer [Indiscernible] quarter of I like changes VAZALORE. earlier first focus any launch, of a obsessed to a or over questions. launch, follow the approval to you're but how just of guess, you've the the other receptivity in of feedback Thanks. observed you're Thanks curious the or the quarter. maybe -- later that end any if in sounds earlier in in for since markets bit on XQ

Thank you.

the plans summer. if in The increased, by I to receptivity, our would are nothing launch else. So has say late retailers

excited now. really They're

excited as for shelf. the product to get premium say I much retailers to won't obvious committed well. terms Very of reasons. too the placement Unfortunately, They've on some in

for top preparing across launch all we're We're a excited. the However, really national retailers.

great. Thank you. that's Okay,

you. Thank

questions. further turn I back At Natasha. Instructions] now the like this to over to time, would there no [Operator are call

disease. our confidence your you believe the and support the their We vascular you. this for of for partners time thank promise the for management our day. and and PLx standard of We Thank at of dedicated care will a appreciate all great for of Thank VAZALORE Have work transform morning. sincerely millions the patients VAZALORE. hard continued the in team for risk shareholders

Thank conference today's concludes call. for participating. you This

You now may disconnect.